GW843682X - Small Molecule (ID:10014-101)

HMS LINCS ID: 10014-101
Name: GW843682X
Alternative Names: GW843682
LINCS ID: LSM-1014
PubChem CID: 9826308
ChEBI ID:
ChEMBL ID:
Molecular Mass: 477.10
InChi: InChI=1S/C22H18F3N3O4S/c1-30-16-7-14-15(8-17(16)31-2)28(11-27-14)19-9-18(20(33-19)21(26)29)32-10-12-5-3-4-6-13(12)22(23,24)25/h3-9,11H,10H2,1-2H3,(H2,26,29)
InChi Key: JSKUWFIZUALZLX-UHFFFAOYSA-N
SMILES: COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=O)N)OCC4=CC=CC=C4C(F)(F)F)OC
Relevant Citations:
Comments:
Date Publicly Available:
Most Recent Update: 2016-05-09

Target Affinity:

(see Study 20000)
Target Affinity Spectrum Value HUGO Gene Name
1
(Kd <100 nM)
FLT3, FLT4, MAPKAPK5, PLK1, PLK3, SLK, TSSK2
2
(equivalent to 100 nM ≤ Kd < 1µM)
ABL1, AXL, BRSK1, CLK4, CSF1R, FLT1, FYN, JAK3, KDR, KIT, MAP4K4, MAP4K5, MELK, NEK2, NTRK1, PDGFRB, PLK4, PRKG1, PTK2, PTK2B, RPS6KA5, STK10, STK3, TSSK1B
3
(equivalent to 1µM ≤ Kd < 10 µM)
AIM1, AKT1, AKT2, AURKA, AURKB, BLK, CAMK1, CAMK2B, CAMK2D, CAMK2G, CDC7, CDK1, CDK2, CHEK2, CHUK, CLK2, CSNK1A1, CSNK1D, CSNK1G1, CSNK1G2, DAPK3, DYRK1A, DYRK3, EEF2K, EPHA2, ERBB2, ERBB4, FGFR1, FGFR3, FLG, GSK3A, GSK3B, HIPK2, HIPK4, IGF1R, IKBKB, INSR, IRAK1, ITK, JAK2, LCK, LIMK1, LYN, MAP4K2, MAPK1, MAPK12, MAPK13, MAPK8, MAPK9, MAPKAPK2, MARK2, MARK3, MET, MINK1, NEK4, NTRK2, PAK4, PASK, PDK1, PDPK1, PHKG2, PIM2, PKN2, PRKAA1, PRKACA, PRKCG, PRKCZ, PRKG2, PRKX, ROCK2, RPS6KA3, RPS6KB1, SRPK1, TYK2
10
(confirmed non-binding)
(Click to show)

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20000
Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library.
Analysis
20001
Moerke 2 Color Apoptosis
Microscopy/Imaging
20002
Moerke 3 Color Apoptosis
Microscopy/Imaging
20004
Tang Proliferation/Mitosis
Microscopy/Imaging
20032
GW843682 KINOMEscan
KINOMEscan
20237
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1.
Microscopy/Imaging
20238
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2.
Microscopy/Imaging
20239
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3.
Microscopy/Imaging
20240
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1.
Microscopy/Imaging
20241
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2.
Microscopy/Imaging
20242
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3.
Microscopy/Imaging
20243
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 15: Mean cell count and mean growth rate across all replicates.
Microscopy/Imaging
20245
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1.
Microscopy/Imaging
20246
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2.
Microscopy/Imaging
20247
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3.
Microscopy/Imaging
20248
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1.
Microscopy/Imaging
20249
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2.
Microscopy/Imaging
20250
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3.
Microscopy/Imaging
20251
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates.
Microscopy/Imaging
20252
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics.
Analysis
20268
Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates.
Analysis
20269
Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics.
Analysis

KINOMEscan Image

Batch Information:

HMS LINCS Batch ID Provider Provider Batch ID
10014-101-1 Haoyuan chemexpress HY-999-20101020
10014-101-2 Axon Medchem aliquoted 5/10
10014-101-3 Sigma-Aldrich